Question · from the living review of Acute Coronary Syndrome Management →

Is it true that FFR-guided PCI and CABG have similar outcomes in multivessel NSTE-ACS?

Uncertain updated weekly · as of

Priors rates this Uncertain — 51 out of 100, updated weekly. It is genuinely uncertain. On the claim that FFR-guided PCI and CABG have similar outcomes in multivessel NSTE-ACS, its four-agent AI review panel weighs the published, peer-reviewed evidence.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Acute Coronary Syndrome Management review.

Related Cardiovascular questions

Is it true that fondaparinux reduces major bleeding versus enoxaparin in NSTE-ACS? → Is it true that high-intensity statins reduce MACE in acute coronary syndrome patients? → Is it true that PCSK9 inhibitors added to statins reduce MACE post-ACS? → Is it true that ACE inhibitors reduce mortality in ACS with reduced ejection fraction? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.